Baseline characteristics of all patients with a first-in-study-period intracerebral haemorrhage ascertained in Oxford Vascular Study (2002–2018) stratified by haematoma location
| Total (n=255)* | Lobar ICH (n=109) | Non-lobar ICH (n=144) | P value | |
| Age (mean/SD) | 75.5/13.1 | 76.4/12.0 | 74.8/13.8 | 0.34 |
| Male sex | 126 (49.4) | 50 (45.9) | 76 (52.8) | 0.28 |
| NIHSS (median, IQR)† | 8 (4–16) | 9 (4–17) | 8 (4–15) | 0.94 |
| Medical history | ||||
| Previous TIA or ischaemic stroke | 73 (28.9) | 39 (35.8) | 34 (23.6) | 0.03 |
| MI or peripheral vascular disease | 21 (8.3) | 15 (13.8) | 6 (4.2) | 0.006 |
| Hypertension | 156 (61.2) | 58 (53.2) | 97 (67.4) | 0.02 |
| Diabetes mellitus | 36 (14.1) | 14 (12.8) | 22 (15.3) | 0.58 |
| Hyperlipidaemia | 59 (23.1) | 24 (22.0) | 35 (24.3) | 0.67 |
| Atrial fibrillation | 57 (22.4) | 24 (22.0) | 33 (22.9) | 0.87 |
| History of smoking‡ | 116 (47.0) | 47 (45.2) | 69 (48.9) | 0.56 |
| Current smoker§ | 24 (9.7) | 10 (9.5) | 14 (9.9) | 0.92 |
| Premorbid medication | ||||
| Antithrombotics¶ | 122 (47.8) | 55 (50.5) | 66 (45.8) | 0.47 |
| Anticoagulants | 54 (21.2) | 27 (24.8) | 27 (18.8) | 0.25 |
| Antiplatelet treatment | 73 (28.6) | 30 (27.5) | 42 (29.2) | 0.77 |
| Antihypertensive treatment | 126 (49.4) | 48 (44.0) | 77 (53.5) | 0.14 |
| Statins | 66 (25.9) | 36 (33.0) | 29 (20.1) | 0.02 |
| Antithrombotics at discharge** | (n=143) | (n=60) | (n=83) | |
| Anticoagulants | 1 (0.7) | 1 (1.7) | 0 (0) | 0.24 |
| Antiplatelet treatment | 7 (4.9) | 5 (8.3) | 2 (2.4) | 0.11 |
Numbers are presented as n (%) unless otherwise stated.
*n=2 with unknown location due to out-of-area death and no imaging was not accessible.
†Data missing for n=6.
‡Data missing for n=8.
§Data missing for n=7.
¶n=5 patients on both anticoagulant and antiplatelet drugs (n=2 for lobar and n=3 for non-lobar).
**Excluding patients that died prior to discharge.
ICH, intracerebral haemorrhage; MI, myocardial infarction; NIHSS, National Institute of Health Stroke Scale; TIA, transient ischaemic attack.